Shanghai Henlius Biotech, Inc. is a global biopharmaceutical company dedicated to providing high-quality, affordable, and innovative biologic medicines for patients worldwide. The company’s focus lies primarily in the fields of oncology, autoimmune diseases, and ophthalmic diseases. Henlius has successfully launched six products in China and three products have received marketing approval in overseas markets. Additionally, 24 indications are approved worldwide, and three marketing applications are currently under review in both China and the EU.

Services include:
– Biologics
– Biosimilars
– Research and Development
– Contract Manufacturing
– Regulatory Affairs

Shanghai Henlius Biotech, Inc. continues to expand its portfolio of innovative biologic medicines while navigating the complexities of the biopharmaceutical landscape. For more information, please visit henlius.com.